An FDA advisory panel will meet in late July to consider allowing 7 peptides to be used by compounding pharmacies.

President Donald Trump signed an executive order to increase research and issue priority review vouchers for clinical use of psychedelics.

Patients with rosacea who experience burning reported that winter months, significant temperature chances, and dietary habits trigger burning.

Funding disruptions by the Trump administration preceded decreases in HIV testing, diagnosis, prevention, and treatment among infants.

The EFFISAYIL ON study demonstrated that IV spesolimab may be an effective rescue therapy for GPP patients on SC spesolimab who experience a GPP flare.

Drug prices have increased overall during President Donald Trump's negotiations on "most favored nation" drug pricing.

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

The US Environmental Protection Agency has delayed making decisions on allowed uses for forever chemicals or PFAS.

Patients with ophiasis may be categorized into 3 distinct subtypes that can guide early intervention and stratify treatment.

Blaine Labs recalls Revitaderm and Tridergel wound care gels due to microbial contamination with Lysinibacillus fusiformis.

Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.

Real-world data on spesolimab have shown rapid improvement in acute flares of GPP, along with a favorable safety profile, according to a systemic review.